Join Growin Stock Community!

達爾膚6523.TW Overview

TW StockBiotech. & Medical
(No presentation for 6523)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

達爾膚（6523）Overall Performance

達爾膚（6523）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

達爾膚（6523） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

達爾膚（6523）Key Information

達爾膚（6523）Profile

Dr. Wu Skincare Co., Ltd. develops and sells skincare and cosmetics products in Taiwan and internationally. The company offers cleansers, masks, toners, serums, lotion/cream/gel, UV/DD creams, and eye care products, as well as makeup and body products. It also provides products for acne and pores, blackheads, dry skin, signs of aging, dull and spotty skin, sensitive skin, whitening, and emergency care. The company offers its products through a network of approximately 2000 sales locations in Mainland China, Myanmar, Thailand, Malaysia, Singapore, Canada, Vietnam, the Philippines, and Japan. Dr. Wu Skincare Co., Ltd. was incorporated in 2003 and is based in Taipei, Taiwan.

達爾膚（6523）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
12.55
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
70.02%
Net Margin
32.66%
Revenue Growth (YoY)
-3.37%
Profit Growth (YoY)
-5.75%
3-Year Revenue Growth
24.60%
3-Year Profit Growth
24.23%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
12.55
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
70.02%
Net Margin
32.66%
Revenue Growth (YoY)
-3.37%
Profit Growth (YoY)
-5.75%
3-Year Revenue Growth
24.60%
3-Year Profit Growth
24.23%
default symbol

6523

達爾膚

117.00D

-0.85%

(-0.01)

  • When is 6523's latest earnings report released?

    The most recent financial report for 達爾膚 (6523) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6523's short-term business performance and financial health. For the latest updates on 6523's earnings releases, visit this page regularly.

  • Where does 6523 fall in the P/E River chart?

    According to historical valuation range analysis, 達爾膚 (6523)'s current price-to-earnings (P/E) ratio is 11.1, placing it in the Watch zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of 6523?

    According to the latest financial report, 達爾膚 (6523) reported an Operating Profit of 110.7M with an Operating Margin of 34.51% this period, representing a decline of 3.47% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6523's revenue growth?

    In the latest financial report, 達爾膚 (6523) announced revenue of 320.76M, with a Year-Over-Year growth rate of 5.46%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6523 have?

    At the end of the period, 達爾膚 (6523) held Total Cash and Cash Equivalents of 266.36M, accounting for 0.14 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6523 go with three margins increasing?

    In the latest report, 達爾膚 (6523) achieved the “three margins increasing” benchmark, with a gross margin of 67.69%%, operating margin of 34.51%%, and net margin of 34.71%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6523's profit trajectory and future growth potential.

  • Is 6523's EPS continuing to grow?

    According to the past four quarterly reports, 達爾膚 (6523)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 2.47. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6523?

    達爾膚 (6523)'s Free Cash Flow (FCF) for the period is 104.74M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 20.28% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.